Revenue
Trailing-twelve-month (TTM) revenue is $1.21 Billion with a year-over-year growth of +0.17%. Revenue represents the total income generated from the company's primary business operations.
TECH Revenue
Reported quarterly revenue; no daily interpolation.
TECH Quarterly Revenue Growth (YoY)
Revenue growth vs the same quarter one year earlier, last 20 quarters.
TECH Revenue by Segment
How TECH’s revenue breaks down across its reported segments in the latest reported fiscal year.
By product / business (FY 2025)
- Consumables$972.29M79.7%
- Instruments$112.09M9.2%
- Royalty$23.69M1.9%
- Unallocated$111.57M9.1%
By geography (FY 2025)
- U S$683.23M56.0%
- Europe$266.31M21.8%
- C N$100.46M8.2%
- APAC, excluding Greater China$77.26M6.3%
- United Kingdom$54.83M4.5%
- Rest Of World$37.55M3.1%
TECH Revenue by Product / Business (history)
How the revenue mix has shifted across the last 3 reported fiscal years. Bar height tracks total revenue.
- Consumables
- Instruments
- Royalty
- Unallocated
TECH Revenue by Geography (history)
How the revenue mix has shifted across the last 6 reported fiscal years. Bar height tracks total revenue.
- U S
- Europe
- C N
- APAC, excluding Greater China
- United Kingdom
- Rest Of World
- Other reported
Revenue (TTM)
$1.21B
$1.21 Billion
Year-over-Year Growth
+0.17%
vs. $1.21B a year ago (TTM)
Revenue CAGR
+7.39%
5 Year compound annual growth rate
Revenue CAGR (Compound Annual Growth Rate)
1 Year
+0.17%
3 Year
+2.52%
5 Year
+7.39%
10 Year
+9.65%
15 Year
+10.29%
20 Year
+9.47%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
Annual Revenue History
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $1.22B | +$60.58M | +5.23% |
| 2024 | $1.16B | +$22.36M | +1.97% |
| 2023 | $1.14B | +$31.10M | +2.81% |
| 2022 | $1.11B | +$174.57M | +18.75% |
| 2021 | $931.03M | +$192.34M | +26.04% |
| 2020 | $738.69M | +$24.68M | +3.46% |
| 2019 | $714.01M | +$71.01M | +11.04% |
| 2018 | $642.99M | +$79.99M | +14.21% |
| 2017 | $563.00M | +$63.98M | +12.82% |
| 2016 | $499.02M | +$46.78M | +10.34% |
Revenue Growth Summary
TTM Growth
+0.17%
3-Year Avg Growth
+2.52%
5-Year Avg Growth
+7.39%
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman